Wednesday, 25 April 2012 10:04
Say has recently launched the results of a pioneering trial run by Synairgen plc (LSE:SNG). Coverage was achieved in The Daily Express, The Daily Mail, The Scotsman, The Daily Mirror and The Sun. Say also secured articles in leading trade publications.
Richard Marsden, Chief Executive of Synairgen, said:
“This is a great result for the development of our programme. To put SNG001’s potential into context, it is estimated that in the US alone there are some 2 to 4 million difficult to treat (Step 4 and 5) adult asthma sufferers who could benefit from this therapy. Children, who get more colds than adults, represent an additional asthma market opportunity. We believe that there will be even greater potential in COPD. We continue to analyse the wealth of data generated by this important trial and to plan the next phase of its development, ideally alongside an industry partner. ”